Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)
QUICKTIME•Episode home
Manage episode 484593885 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics:
- Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00)
- Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax (7:03)
- Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35)
- Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28)
- Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease (15:52)
- Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12)
- Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor (19:38)
- Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment (22:15)
- Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13)
- Available data with epcoritamab monotherapy for R/R CLL (26:58)
- The emerging pharmacologic class of BTK degraders (29:04)
1545 episodes
QUICKTIME•Episode home
Manage episode 484593885 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics:
- Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00)
- Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax (7:03)
- Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35)
- Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28)
- Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease (15:52)
- Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12)
- Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor (19:38)
- Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment (22:15)
- Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13)
- Available data with epcoritamab monotherapy for R/R CLL (26:58)
- The emerging pharmacologic class of BTK degraders (29:04)
1545 episodes
Усі епізоди
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.